Shares of Aspreva slumped today after it announced that CellCept failed a late-stage trial comparing the drug to standard lupus therapy. Aspreva and Roche are developing the drug. Response rates for both therapies were similar and did not demonstrate CellCept's superiority to intravenous cyclophosphamide--the study's primary goal. The trial included 370 volunteers. Aspreva says that it is analyzing the results as it evaluates a possible regulatory filing.
- check out this release
- here's the report from Hemscott